Hereditary Cancer Syndromes (BRCA1/BRCA2)
Prevalence: 1 in 400 general population; 1 in 40 Ashkenazi Jewish individuals carry a BRCA founder mutation
BRCA1 and BRCA2 mutations cause hereditary breast and ovarian cancer syndrome (HBOC). Lifetime breast cancer risk reaches 65-85% for BRCA1 carriers. PARP inhibitors exploit synthetic lethality in BRCA-deficient tumors.
Peptide Therapeutics
BRCT domain-mimetic peptides, peptide-drug conjugates targeting BRCA-deficient cells via synthetic lethality, cell-penetrating repair peptides, and tumor-homing peptides for targeted delivery.
Current Treatments
PARP inhibitors (olaparib, talazoparib, rucaparib), prophylactic surgery, enhanced surveillance, platinum chemotherapy.
Key Genetic Variants
Associated Genes
Tumor suppressor essential for DNA double-strand break repair via homologous recombination. Loss of function leads to genomic instability and dramatically increased cancer risk.
Explore peptide candidates for Hereditary Cancer Syndromes (BRCA1/BRCA2)
Submit rs121918506 to PepFold. Full report with 3D structures and synthesis protocols in under 2 minutes.